Follow
Enrique Seoane Vazquez
Enrique Seoane Vazquez
Chapman University School of Pharmacy
Verified email at chapman.edu - Homepage
Title
Cited by
Cited by
Year
Market withdrawal of new molecular entities approved in the United States from 1980 to 2009
ZP Qureshi, E Seoane‐Vazquez, R Rodriguez‐Monguio, KB Stevenson, ...
Pharmacoepidemiology and drug safety 20 (7), 772-777, 2011
1672011
Incentives for orphan drug research and development in the United States
E Seoane-Vazquez, R Rodriguez-Monguio, SL Szeinbach, J Visaria
Orphanet journal of rare diseases 3 (1), 1-7, 2008
1462008
Dispensing errors in community pharmacy: perceived influence of sociotechnical factors
S Szeinbach, E Seoane-Vazquez, A Parekh, M Herderick
International Journal for Quality in Health Care 19 (4), 203-209, 2007
932007
The impact of allergic rhinitis on work productivity
SL Szeinbach, EC Seoane-Vazquez, A Beyer, PB Williams
Primary Care Respiratory Journal 16 (2), 98-105, 2007
842007
Incorporating indications into medication ordering—time to enter the age of reason
G Schiff, E Seoane-Vazquez, A Wright
642016
Exogenous endoscopy-related infections, pseudo-infections, and toxic reactions: clinical and economic burden
E Seoane-Vazquez, R Rodriguez-Monguio, J Visaria, A Carlson
Current medical research and opinion 22 (10), 2007-2021, 2006
562006
Ethical imperatives of timely access to orphan drugs: is possible to reconcile economic incentives and patients’ health needs?
R Rodriguez-Monguio, T Spargo, E Seoane-Vazquez
Orphanet journal of rare diseases 12 (1), 1-8, 2017
522017
Endoscopy-related infections and toxic reactions: an international comparison
E Seoane-Vazquez, R Rodriguez-Monguio, J Visaria, A Carlson
Endoscopy 39 (08), 742-778, 2007
522007
The landscape of cellular and gene therapy products: authorization, discontinuations, and cost
V Shukla, E Seoane-Vazquez, S Fawaz, L Brown, R Rodriguez-Monguio
Human Gene Therapy Clinical Development 30 (3), 102-113, 2019
502019
Approval and withdrawal of new antibiotics and other antiinfectives in the US, 1980–2009
K Outterson, JH Powers, E Seoane‐Vazquez, R Rodriguez‐Monguio, ...
The Journal of Law, Medicine & Ethics 41 (3), 688-696, 2013
502013
Endoscopy-related infection: relic of the past?
E Seoane-Vazquez, R Rodriguez-Monguio
Current opinion in infectious diseases 21 (4), 362-366, 2008
492008
Innovation and competition in advanced therapy medicinal products
E Seoane‐Vazquez, V Shukla, R Rodriguez‐Monguio
EMBO molecular medicine 11 (3), e9992, 2019
432019
International critical care hospital pharmacist activities
JM LeBlanc, EC Seoane-Vazquez, TC Arbo, JF Dasta
Intensive care medicine 34 (3), 538-542, 2008
402008
Using a machine learning system to identify and prevent medication prescribing errors: a clinical and cost analysis evaluation
R Rozenblum, R Rodriguez-Monguio, LA Volk, KJ Forsythe, S Myers, ...
The Joint Commission Journal on Quality and Patient Safety 46 (1), 3-10, 2020
362020
Incorporating medication indications into the prescribing process
K Kron, S Myers, L Volk, A Nathan, P Neri, A Salazar, MG Amato, A Wright, ...
The Bulletin of the American Society of Hospital Pharmacists 75 (11), 774-783, 2018
352018
Fixed-dose combination drug approvals, patents and market exclusivities compared to single active ingredient pharmaceuticals
J Hao, R Rodriguez-Monguio, E Seoane-Vazquez
PLoS One 10 (10), e0140708, 2015
332015
Evaluation of causes and frequency of medication errors during information technology downtime
TL Hanuscak, SL Szeinbach, E Seoane-Vazquez, BJ Reichert, ...
American Journal of Health-System Pharmacy 66 (12), 1119-1124, 2009
322009
Priority review drugs approved by the FDA and the EMA: time for international regulatory harmonization of pharmaceuticals?
S Alqahtani, E Seoane‐Vazquez, R Rodriguez‐Monguio, T Eguale
Pharmacoepidemiology and Drug Safety 24 (7), 709-715, 2015
312015
Drug utilization and cost in a Medicaid population: A simulation study of community vs. mail order pharmacy
S Valluri, E Seoane-Vazquez, R Rodriguez-Monguio, SL Szeinbach
BMC Health Services Research 7 (1), 1-9, 2007
312007
Good research practices for measuring drug costs in cost‐effectiveness analyses: Medicare, Medicaid and other US government payers perspectives: the ISPOR Drug Cost Task Force …
CD Mullins, B Seal, E Seoane‐Vazquez, J Sankaranarayanan, CV Asche, ...
Value in Health 13 (1), 18-24, 2010
302010
The system can't perform the operation now. Try again later.
Articles 1–20